5 results found
Maynard S, Ros-Soto J, Chaidos A, et al., 2021, The role of ibrutinib in COVID-19 hyperinflammation: a case report, International Journal of Infectious Diseases, Vol: 105, Pages: 274-276, ISSN: 1201-9712
Continuing ibrutinib in patients with COVID-19 may be advantageous given its immunomodulatory properties and withdrawal of ibrutinib therapy may be detrimental. Further evidence is required to explore the potential therapeutic impact of BTKis and other immunomodulatory agents on the clinical course of COVID-19 as is currently being carried out in a number of clinical trials.
Claudiani S, Apperley JF, Deplano S, et al., 2016, Cognitive dysfunction after withdrawal of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia, American Journal of Hematology, Vol: 91, Pages: E480-E481, ISSN: 1096-8652
Neelakantan P, Rezvani K, May P, et al., 2014, Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side effects, BRITISH JOURNAL OF HAEMATOLOGY, Vol: 164, Pages: 608-610, ISSN: 0007-1048
Milojkovic D, Apperley J, 2008, State-of-the-art in the treatment of chronic myeloid leukaemia, CURRENT OPINION IN ONCOLOGY, Vol: 20, Pages: 112-121, ISSN: 1040-8746
De Melo VA, Milojkovic D, Khorashad JS, et al., 2007, Philadelphia-negative clonal haematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukaemia, Blood, Vol: 110, Pages: 3086-3087
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.